-
1مؤتمر
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
2دورية أكاديمية
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
3دورية أكاديمية
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
4دورية أكاديمية
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
5دورية أكاديمية
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
6
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
العلاقة: https://figshare.com/articles/dataset/Demographics_of_pasireotide_and_control_groups_/14849267Test
-
7
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
8صورة
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
9صورة
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide
-
10
المؤلفون: Sendhilnathan Ramalingam (9368069), Sharareh Siamakpour-Reihani (218652), Lauren Bohannan (11028020), Yi Ren (30049), Alexander Sibley (4544248), Jeff Sheng (11028023), Li Ma (46633), Andrew B. Nixon (11028026), Jing Lyu (2795911), Daniel C. Parker (7592912), James Bain (602283), Michael Muehlbauer (268033), Olga Ilkayeva (715991), Virginia Byers Kraus (184450), Janet L. Huebner (8716845), Thomas Spitzer (11028029), Jami Brown (11028032), Jonathan U. Peled (11028035), Marcel van den Brink (541863), Antonio Gomes (11028038), Taewoong Choi (9368081), Cristina Gasparetto (4889671), Mitchell Horwitz (9368090), Gwynn Long (11028041), Richard Lopez (11028044), David Rizzieri (6205928), Stefanie Sarantopoulos (210427), Nelson Chao (4889674), Anthony D. Sung (6205916)
مصطلحات موضوعية: Microbiology, Cell Biology, Genetics, Biotechnology, Immunology, Developmental Biology, Marine Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, attenuated post-HCT loss, survival, pasireotide group, GI, log-rank p, OS, RFS, toxicity, IL, marker, myeloablative allogeneic HCT, pre-to-post transplant changes, CI, stool diversity index, MIP 1a MIP 1b TNFa, somatostatin analog pasireotide, cell transplant Background Allogene., phase 2 trial, GVHD, 0.9 mg pasireotide